Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hisamitsu buys remaining 95.1% of Noven for $408mm in cash

Executive Summary

Hisamitsu Pharmaceutical, a 162-year-old company that claims to be the largest therapeutic patch manufacturer in the world, has agreed to acquire the remaining 95.1% of Noven Pharmaceuticals (drug delivery technologies) that it does not already own for about $408mm. Noven investors will receive $16.50 in cash (a 17% premium) for each share. Hisamitsu initially gained a 4.9% stake in 2002.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Transdermal
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies